Decision-making associated with drug candidates in the biotechnology research and development (R&D) pipeline

Journal of Commercial Biotechnology

Volumn 13, Issue 2, 2007, Pages 99-110

  Skrepnek, Grant H ^a   Sarnowski, Jeff J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERNAL RATE OF RETURN (IRR); NET PRESENT VALUE (NPV); PHARMACOECONOMICS;

COSTS; DECISION MAKING; DRUG PRODUCTS; ECONOMICS; RESEARCH AND DEVELOPMENT MANAGEMENT;

BIOTECHNOLOGY;

ARTICLE; BIOTECHNOLOGY; CAPITAL; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; ECONOMIC EVALUATION; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH ECONOMICS; MEDICAL RESEARCH; PRODUCT DEVELOPMENT; PROSPECTIVE PRICING; REIMBURSEMENT; RISK ASSESSMENT; STRATEGIC PLANNING; UNITED STATES;

EID: 34447277171     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jcb.3050040     Document Type: Article

References (40)

1. Garvin, D. A. & Roberto, M. (2001). What you don't know about making decisions. Harvard Bus. Rev. 79, 108-116.
2. Blau, G. E., Pekny, J. F., Varma, V. A. & Bunch, P. R. (2004). Managing a portfolio of interdependent new product candidates in the pharmaceutical industry. J. Prod. Innovat. Manage. 21, 227-245.
3. Congressional Budget Office. (2006). Research and development in the pharmaceutical industry, Publication No. 2589, Congress of the United States, Washington, D.C.
4. Tyebjee, T. & Hardin, J. (2004). Biotech-pharma alliances: Strategies, structures and financing. J. Comm. Biotechnol. 10, 329-339.
5. Valentine, E.L. (2003). Business development: A barometer of future success. J. Comm. Biotechnol. 10, 123-130.
6. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. J. Health Econ. 22, 151-185.
7. Fildes, R. A. (1990). Strategic challenges in commercializing biotechnology.California Manage. Rev. 32, 63-72.
8. McCutchen, W. W. & Swamidass, P. M. (1996). Effect of R & D expenditures and funding strategies on the market value of biotech firms. J. Eng. Technol. Manage. 12, 287-299.
9. Skrepnek, G. H. (2004). Accounting- versus economic-based rates of return: Implications for profi tability measures in the pharmaceutical industry. Clin. Therapeut. 26, 155-174.
10. Hogaboam, L. S. & Shook, S. R. (2004). Capital budgeting practices in the US forest products industry: A reappraisal.Forest Prod. J. 54, 149-158.
11. Lam, M. D. (2004). Knowing when to pull the plug on your experimental drug: How to succeed by failing faster. Pharmaceut. Exec. 2, 55-60.
12. Bonabeau, E. (2003). Don't trust your gut. Harvard Bus. Rev. 81 116-123.
13. Center for Medicine Research (CMR) International. (1997). Portfolio management by leading pharmaceutical companies: Current approaches to decision making, Publication CMR97-84R, CMR International, Surrey, United Kingdom.
14. Loch, C. H. & Bode-Greuel, K. (2001). Evaluating growth options as sources of value for pharmaceutical research projects. R&D Manage. 31, 231-248.
15. Krishnan, V. & Ulrich, K. T. (2001). Product development decisions: A review of the literature. Manage. Sci. 47, 1-21.
16. Sharpe, P. & Keelin, T. (1998). How SmithKline Beecham makes better resource-allocation decisions. Harvard Bus. Rev. 76, 45-57.
17. Newton, D. P., Paxson, D. A. & Widdicks, M. (2004). Real R&D options. Int. J. Manage. Rev. 5/6, 113-130.
18. Villiger, R. & Bogan, B. (2005). Valuing pharma R & D: The catch-22 of DCF. J. Appl. Corp. Fin. 17, 113-116.
19. DiMasi, J. A., Caglarcan, E. & Wood-Armany, M. (2001). Emerging role of pharmacoeconomics in the research and development decision-making process.Pharmacoeconomics 19, 753-766.
20. Skrepnek, G.H. (2005). Cost-effectiveness analysis, in Bootman, J.L., Townsend, R.J., McGhan, W.F., (eds.), Principles of Pharmacoeconomics (3rd edn) W Harvey Whitney Books Company, Cincinnati, Ohio.
21. Miller, P. (2005). Role of pharmacoeconomic analysis in R & D decision making. Pharmacoeconomics 23, 1-12.
22. Dilman, D. A. (1978). Mail and Telephone Surveys: The Total Design Method, John Wiley and Sons, New York, New York.
23. Graham, J. R. & Harvey, C. R. (2001). The theory and practice of corporate finance: Evidence from the field. J. Financ. Econ. 60 187-243.
24. Trahan, E. A. & Gitman, L. J. (1995). Bridging the theory-practice gap in corporate fi nance: A survey of chief financial officers. Q. Rev. Econ. Financ. 31, 77-88.
25. Ryan, P. A. & Ryan, G. P. (2002). Capital budgeting practices of the Fortune 1000: How have things changed? J. Bus. Manage. 8, 355-364.
26. Grabowski, H., Cockburn, I. & Long, G. (2006). The market for follow-on biologics: How will it evolve? Health Affairs 25, 1291-1301.
27. Pisano, G. P. (2006). Can science be a business? Lessons from biotech. Harvard Bus. Rev. 10, 114-125.
28. McCutchen, W. W. & Swamidass, P. M. (2004). Motivations for strategic alliances in the pharmaceutical/biotech industry: Some new findings. J. High Technol. Manage. Res. 15, 197-214.
29. Danzon, P. M., Nicholson, S. & Pereira, N. S. (2005). Productivity in pharmaceuticalbiotechnology R&D: The role of experience and alliances. J. Health Econ. 24, 317-339.
30. Bound, J., Cummins, C., Griliches, Z., Hall, B. H. & Jaffe, A. (1984). Who does R&D and who patents?, in Griliches, Z. (ed.), R&D Patents, and Productivity. National Bureau of Economic Research, University of Chicago Press, Chicago, Illinois.
31. Grabowski, H. G. & Vernon, J. M. (2000). The determinants of pharmaceutical research and development expenditures. J. Evolut. Econ. 10, 201-215.
32. Istvan, D. F. (1961). Capital-expenditure decisions: How are they made in large corporations. Bureau of Business Research, Indiana University, Bloomington, Indiana.
33. Pike, R. (1996). A longitudinal survey on capital budgeting practices. J. Bus. Financ. Account. 23, 79-92.
34. Jog, V. M. & Srivastava, A. K. (1995). Capital budgeting practices in corporate Canada. Financ. Pract. Educ. 5, 37-43.
35. Stonebraker, J. S. (2002). How Bayer makes decisions to develop new drugs. Interfaces 32 (6), 77-90.
36. Khatri, N. & Alvin, H. (2000). The role of intuition in strategic decision making.Hum. Relat. 53, 57-86.
37. Sinclair, M. & Ashkanasy, N. M. (2005). Intuition: Myth or a decision-making tool? Manage. Learn. 36, 353-370.
38. Skrepnek, G. H. (2006). The contrast and convergence of Bayesian and frequentist approaches in pharmacoeconomic analysis, Working Paper, Center for Health Outcomes and Pharmacoeconomic Research, The University of Arizona, Tucson, Arizona.
39. Motheral, B. R., Grizzle, A. J., Armstrong, E. P., Cox, E. & Fairman, K. (2000). Role of pharmacoeconomics in drug benefit decisionmaking: Results of a survey. Formulary 35, 412-421.
40. Hatfield, H. A., Horvath, P. A. & Webster, A. (1998). Financial criteria, capital budgeting techniques, risk analysis and manufacturing firm performance. Working Paper, Annual Meeting of the Multinational Financial Society; Helsinki, Finland.